The identification of driver oncogenes, such as mutations or rearrangements in the epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) genes, along with the subsequent development of molecular-targeted therapies has marked the initiation of a new era in precision medicine tailored for the management of NSCLC [5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.